Results 71 to 80 of about 114,465,275 (302)

Initial Testing of Topotecan by the Pediatric Preclinical Testing Program [PDF]

, 2010
Background. Topotecan is a small molecule DNA topoisomerase poison, that has been successful in clinical trials against pediatric solid tumors and leukemias. Topotecan was evaluated against the Pediatric Preclinical Testing Program (PPTP) tumor panels as
Houghton, PJ, Carol, H, Lock, RB ; https://orcid.org/, Reynolds, CP, Smith, MA, Watkins, A, Kang, MH, Morton, CL, Kolb, EA, Maris, JM, Gorlick, R, Keir, ST   +11 more
core   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

TCR-T cell therapy: current development approaches, preclinical evaluation, and perspectives on regulatory challenges

Journal of Translational Medicine
TCR-T cell therapy represents a promising advancement in adoptive immunotherapy for cancer treatment. Despite its potential, the development and preclinical testing of TCR-T cells face significant challenges. This review provides a structured overview of
Elena A. Golikova, Alina A. Alshevskaya, Saleh Alrhmoun, Natalia A. Sivitskaya, Sergey V. Sennikov   +4 more
doaj   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Human ubiquitin-like proteins as central coordinators in autophagy [PDF]

, 2018
International audienceAutophagy is one of the most versatile recycling systems of eukaryotic cells. It degrades diverse cytoplasmic components such as organelles, protein aggregates, ribosomesand multi-enzyme complexes.
Wollert, Thomas, Mohan, Jagan
core   +1 more source

Three-Dimensional Spheroids as In Vitro Preclinical Models for Cancer Research

Pharmaceutics, 2020
Most cancer biologists still rely on conventional two-dimensional (2D) monolayer culture techniques to test in vitro anti-tumor drugs prior to in vivo testing.
Bárbara Pinto, Ana C. Henriques, Patrícia M. A. Silva, Hassan Bousbaa   +3 more
doaj   +1 more source

In Vitro Preclinical Testing of Nonoxynol-9 as Potential Anti-Human Immunodeficiency Virus Microbicide: a Retrospective Analysis of Results from Five Laboratories [PDF]

Antimicrobial Agents and Chemotherapy, 2006
ABSTRACT The first product to be clinically evaluated as a microbicide contained the nonionic surfactant nonoxynol-9 (nonylphenoxypolyethoxyethanol; N-9). Many laboratories have used N-9 as a control compound for microbicide assays.
Brigitte E, Beer, Gustavo F, Doncel, Fred C, Krebs, Robin J, Shattock, Patricia S, Fletcher, Robert W, Buckheit, Karen, Watson, Charlene S, Dezzutti, James E, Cummins, Ena, Bromley, Nicola, Richardson-Harman, Luke A, Pallansch, Carol, Lackman-Smith, Clay, Osterling, Marie, Mankowski, Shendra R, Miller, Bradley J, Catalone, Patricia A, Welsh, Mary K, Howett, Brian, Wigdahl, Jim A, Turpin, Patricia, Reichelderfer   +21 more
openaire   +2 more sources

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Preclinical Data on Efficacy of 10 Drug-Radiation Combinations: Evaluations, Concerns, and Recommendations

Translational Oncology, 2016
BACKGROUND: Clinical testing of new therapeutic interventions requires comprehensive, high-quality preclinical data. Concerns regarding quality of preclinical data have been raised in recent reports. This report examines the data on the interaction of 10
Helen B. Stone, Eric J. Bernhard, C. Norman Coleman, James Deye, Jacek Capala, James B. Mitchell, J. Martin Brown   +6 more
doaj   +1 more source

An ex vivo model of medical device-mediated bacterial skin translocation

Scientific Reports, 2021
The skin is a barrier and part of the immune system that protects us from harmful bacteria. Because indwelling medical devices break this barrier, they greatly increase the risk of infection by microbial pathogens.
Hao Wang, Anant Agrawal, Yi Wang, David W. Crawford, Zachary D. Siler, Marnie L. Peterson, Ricky T. Woofter, Mohamed Labib, Hainsworth Y. Shin, Andrew P. Baumann, K. Scott Phillips   +10 more
doaj   +1 more source